Liu ZM - Search Results

1

Frizzled receptors (FZDs) in Wnt signaling: potential therapeutic targets for human cancers.

Liu HY, Sun XJ, Xiu SY, Zhang XY, Wang ZQ, Gu YL, Yi CX, Liu JY, Dai YS, Yuan X, Liao HP, Liu ZM, Pang XC, Li TC. Liu HY, et al. Among authors: liu zm. Acta Pharmacol Sin. 2024 Apr 17. doi: 10.1038/s41401-024-01270-3. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 38632318 Review.

2

Urea-containing peptide boronic acids as potent proteasome inhibitors.

Han LQ, Yuan X, Wu XY, Li RD, Xu B, Cheng Q, Liu ZM, Zhou TY, An HY, Wang X, Cheng TM, Ge ZM, Cui JR, Li RT. Han LQ, et al. Among authors: liu zm. Eur J Med Chem. 2017 Jan 5;125:925-939. doi: 10.1016/j.ejmech.2016.10.023. Epub 2016 Oct 14. Eur J Med Chem. 2017. PMID: 27769033

3

Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.

Huang W, Liu Y, Wang J, Yuan X, Jin HW, Zhang LR, Zhang JT, Liu ZM, Cui JR. Huang W, et al. Among authors: liu y, liu zm. Eur J Med Chem. 2018 Sep 5;157:887-897. doi: 10.1016/j.ejmech.2018.08.037. Epub 2018 Aug 14. Eur J Med Chem. 2018. PMID: 30145375 Free article.

4

Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening.

Chen Y, Yuan X, Xiao Z, Jin H, Zhang L, Liu Z. Chen Y, et al. PLoS One. 2018 Oct 15;13(10):e0205175. doi: 10.1371/journal.pone.0205175. eCollection 2018. PLoS One. 2018. PMID: 30321196 Free PMC article.

5

Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.

Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q, Cui Y. Xiang Q, et al. Pharmacol Ther. 2019 Nov;203:107393. doi: 10.1016/j.pharmthera.2019.107393. Epub 2019 Jul 26. Pharmacol Ther. 2019. PMID: 31356909 Free article. Review.

6

Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study.

Dou X, Sun X, Huang H, Jiang L, Jin Z, Liu Y, Zou Y, Li Z, Zhu G, Jin H, Jiao N, Zhang L, Liu Z, Zhang L. Dou X, et al. Eur J Med Chem. 2022 Apr 5;233:114196. doi: 10.1016/j.ejmech.2022.114196. Epub 2022 Feb 23. Eur J Med Chem. 2022. PMID: 35231830

7

DTX-P7, a peptide-drug conjugate, is highly effective for non-small cell lung cancer.

Jiang Y, Huang W, Sun X, Yang X, Wu Y, Shi J, Zheng J, Fan S, Liu J, Wang J, Liang Z, Yang N, Liu Z, Liu Y. Jiang Y, et al. J Hematol Oncol. 2022 Jun 3;15(1):73. doi: 10.1186/s13045-022-01274-8. J Hematol Oncol. 2022. PMID: 35659720 Free PMC article.

8

Recent advances in gout drugs.

Shi C, Zhou Z, Chi X, Xiu S, Yi C, Jiang Z, Chen R, Zhang L, Liu Z. Shi C, et al. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114890. doi: 10.1016/j.ejmech.2022.114890. Epub 2022 Oct 29. Eur J Med Chem. 2023. PMID: 36335742 Review.

9

The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer.

Sun X, Zhang Z, Wang Z, Xie R, Yi C, Liu H, Chi X, Li T, Liu H, Han Y, Pang X, Cui Y, Liu Z. Sun X, et al. Front Immunol. 2022 Nov 21;13:1033967. doi: 10.3389/fimmu.2022.1033967. eCollection 2022. Front Immunol. 2022. PMID: 36479101 Free PMC article.

10

Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer.

Pang X, Sun X, Gu Y, He X, Gong K, Song S, Zhang J, Xia J, Liu Z, Cui Y. Pang X, et al. Signal Transduct Target Ther. 2023 Feb 10;8(1):60. doi: 10.1038/s41392-022-01236-z. Signal Transduct Target Ther. 2023. PMID: 36759595 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

798 results

Search Page